PharmaTimes


	Website and Archive search
	Go

	JobSearch
	Go

Email

Password

Subscribe to the archive

Forgotten password

	MAGAZINE AUDIT BY


	Where am I? > Home

LATEST WORLD NEWS

Solid results for Amgen but all eyes on denosumab
Amgen’s adjusted net income for the second quarter has edged up 1% to $1.33 billion, while turnover was up 2% to $3.80 billion

GSK pays out $15 million to option Anacor antibiotic
GlaxoSmithKline has exercised its option to develop an antibiotic from Anacor Pharmaceuticals which has shown potential in early-stage studies

More World News articles

Merck KGaA earnings shoot up, profit forecast raised
Merck KGaA has posted a strong set of figures for the second quarter this morning, which reveal that earnings jumped 70.1%

NiCox still optimistic after naproxcinod failure in USA
Fresh from having its pain product naproxcinod rejected by the FDA, NicOx has posted its financial results for the first six months of 2010 which show that the French biotech is still in a reasonable state, cashwise

LATEST JOBS

Junior Editor, Healthcare Communications

Hospital Specialist - Northern & Western Home Counties

PRODUCT MANAGER - HOMECARE

Part-time Medical Representative

Medical Scientific Liaison Representative

Regional Account Manager/Business Manager

Territory Manger- North-West

GP/Hospital Representative

Product and Promotions Manager - Aesthetics

Consulting careers in International Life-Sciences Executive Search

LATEST CLINICAL NEWS

ICON lowers guidance as Q2 operating income declines 12%

Volume of UK animal experiments down by 1% in 2009

Expenses drag down PPD income in Q2

PharmaNet, Abacus ally on ‘real world' research

More UK News articles


Join PharmaTimes Directors Club
	Find out more


PharmaTimes Club for Directors Secretaries
	Learn more

PHARMATIMES MAGAZINE FEATURE

The information highway
Peter Mansell explores the sometimes contentious relationship between journalism and the PR sector

Putting the patient at the centre
Relying on high-tech channels to achieve
success in patient programmes ignores one
fundamental point, says Adam Fleming
– the patient should be at the centre of your
planning

	More articles
	Subscribe

	More articles
	Subscribe